异基因造血干细胞移植后脓毒性休克:多中心ICU队列的结局与预后因素
该多中心回顾性队列纳入2015至2020年ICU收治的异基因造血干细胞移植(allo-HSCT)后脓毒性休克患者,占ICU住院移植受者的38%(444/1164)。90天和3年死亡率分别为63%和81%。真菌病原学证据、SOFA评分和中性粒细胞缺乏与90天生存独立相关;早期氨基糖苷类使用与较高90天生存相关但随时间变化,不支持简单因果解读。
要点
- allo-HSCT后脓毒性休克患者90天死亡率达63%,3年死亡率达81%。
- 真菌病原学证据、SOFA评分和中性粒细胞缺乏是90天生存的独立预后因素。
- 早期氨基糖苷类使用与较高90天生存相关,但时间变化分析提示关联复杂,需前瞻性验证。
核心结论
- allo-HSCT后脓毒性休克死亡率高,90天死亡率为63%。
- 预后主要由宿主相关因素和初始疾病严重程度驱动。
- 氨基糖苷类使用与结局的关联复杂,不支持直接因果解释。
研究设计与样本
- 多中心回顾性队列研究,纳入2015至2020年ICU收治的allo-HSCT后脓毒性休克受者。
- 在1164例ICU住院的allo-HSCT受者中,444例(38%)因脓毒性休克入ICU。
主要发现
- 中位SOFA评分为8(四分位距6-11)。
- 62%(261例)获得微生物学证据,其中真菌病原体占17%(74例)。
- 呼吸道是最常见感染来源(43%,180例)。
- 64%(284例)需要有创机械通气,32%(143例)需要肾脏替代治疗。
- 90天死亡率为63%(280例),3年死亡率为81%(350例)。
关键数值与推荐
- 年龄≥56岁(HR 1.36,95%CI 0.99-1.87)、GVHD类型和早期细菌病原学证据(HR 0.90,95%CI 0.64-1.26)与90天生存无显著关联。
临床怎么用
- 对allo-HSCT后脓毒性休克患者应识别真菌病原学证据、高SOFA评分和中性粒细胞缺乏等高危因素。
- 早期氨基糖苷类使用与结局的关联需结合时间变化审慎解读,不宜直接推导因果。
局限性
- 回顾性队列设计可能引入偏倚。
- 氨基糖苷类使用与结局的关联随时间变化,不支持简单因果解释。
- 氨基糖苷类与结局的关系需进一步前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Septic shock is a major cause of ICU admission among recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet data on its epidemiologic features and prognosis remain limited. RESEARCH QUESTION: What are the outcomes, independent prognostic factors, and associations of allo-HSCT that may inform early management? STUDY DESIGN AND METHODS: We performed a multicenter retrospective cohort study including recipients of allo-HSCT admitted to the ICU with septic shock between 2015 and 2020. RESULTS: Among 1,164 recipients of allo-HSCT hospitalized in ICU, 38% (n = 444) were admitted for septic shock. The median Sequential Organ Failure Assessment (SOFA) score was 8 (interquartile range, 6-11). Microbiological documentation was obtained in 62% (n = 261), including fungal pathogens in 17% (n = 74). The respiratory tract was the most common infection source (43%; n = 180). Invasive mechanical ventilation and renal replacement therapy were required in 64% (n = 284) and 32% (n = 143), respectively. Mortality at 90 days and 3 years was 63% (n = 280) and 81% (n = 350), respectively. In the extended Cox model, fungal documentation (hazard ratio [HR], 1.78 [95% CI, 1.19-2.67]; P = .005), SOFA score (HR, 1.07 [95% CI, 1.02-1.13]; P = .007), and neutropenia (HR, 3.94 [95% CI, 1.18-13.1]; P = .026) were associated independently with 90-day survival. In a 48-hour landmark analysis, early aminoglycoside use was associated with higher 90-day survival (HR, 0.46 [95% CI, 0.33-0.64]; P < .001). However, time-varying analyses indicated a nonconstant association over time. Age of ≥ 56 years (HR, 1.36 [95% CI, 0.99-1.87]), graft-versus-host disease type, and early bacterial documentation (HR, 0.90 [95% CI, 0.64-1.26]) were not associated with 90-day survival. INTERPRETATION: Our results show that septic shock after allo-HSCT carries a high mortality (63% at 90 days), largely driven by host-related factors and initial illness severity. The association between aminoglycoside use and outcome is complex, does not support a straightforward causal interpretation, and warrants further prospective evaluation.
引用
- Subileau M, Chean D, Dupont T, et al. Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation: Outcomes and Prognostic Factors in a Multicenter ICU Cohort. Chest. 2026. PMID: 42665126. doi:10.1016/j.chest.2026.06.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。